Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
GEN1286 looks dead, though MCLA-129 continues for now.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
And the company says it won’t need to carry out another trial.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
